Ss Pharmaceutical Co., Ltd.

Ssp Co. Ltd

Dojin Iyaku Kako Co., Ltd.

Hideyoshi Kanbe

Akira Iwasa

Shuichi Kasai

Yoichi Sawayanagi

Yukihiro Saito

Youichi Nakajima

Shuji Yamauchi

Misao Murata

Masunari Fushimi

A preparation for oral administration which comprises S-(3-hydroxypropyl)-L-cysteine and one or more excipients, where the excipients do not cause discoloration of S-(3-hydroxypropyl)-L-cysteine is disclosled. According to an embodiment of the invention, the excipient may comprise a starch and/or a cyclodextrin. Typical starches used in the invention include corn starch, potato starch, wheat starch, and rice starch. Typical cyclodextrins used in the invention include &agr;-cyclodextrin, &bgr;-cyclodextrin, and &ggr;-cyclodextrin. Other excipients, such as saccharides, sugar alcohols and cellulose are not present in amounts that cause discoloration of the HPCY.

Oral preparations comprising S-(3-hydroxypropyl)-L-cysteine

A process is provided for the production of piroxicam tablets. According to the process, a solution of a water-soluble high-molecular substance is added to a mixture of piroxicam and lactose. The resultant mixture is granulated and then compressed into tablets.

Piroxicam tablets and production and process thereof

A sustained-release pranoprofen preparation is disclosed. The preparation comprises an effective amount of pranoprofen and one or more sustained-release components selected from the group consisting of oily components, water-soluble components, water-insoluble components, and intestinally soluble components. It controls release of pranoprofen and lowers the maximum pranoprofen concentration in blood, maintaining its concentration in blood at a certain level for a long period of time. It reduces risks of side effects and can effectively treat diseases with dosing once or twice a day.

Sustained-release pranoprofen preparation

Growing community of inventors

Ichikawa, Japan

Hideyoshi Kanbe